The usefulness of arbekacin compared to vancomycin

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 7, 2012, Pages 1663-1666

  Hwang, J H ^a   Lee, J H ^a,b   Moon, M K ^a   Kim, J S ^a   Won, K S ^a   Lee, C S ^b,c  

^a Chonbuk National University   (South Korea)

^b Chonbuk National University Medical School and Hospital   (South Korea)

^c Chonbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HABEKACIN; METICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT; DIBEKACIN; DRUG DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG TREATMENT FAILURE; FEMALE; HOSPITAL ADMISSION; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; COMPARATIVE STUDY; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; DIBEKACIN; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84865600208     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1490-9     Document Type: Article

References (23)

1. Ma XX, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Vavra S, Daum RS, Hiramatsu K (2002) Novel type of staphylococcal cassette chromosome mec identified in communityacquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 46(4):1147-1152
2. Chung GT, Cha JG, Han SY, Jang HS, Lee KM, Yoo JI, Yoo JS, Kim HB, Eun SH, Kim BS, Park O, Lee YS (2010) Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean Hospitals from 2001 to 2006. J Microbiol Biotechnol 20(3):637-642
3. Lee KW, Lee MA, Lee CH, Lee JW, Roh KH, Kim SJ, Kim JJ, Koh EM, Yong DE, Chong YS, KONSAR Group (2010) Increase of ceftazidime-and fluoroquinolone- resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: Analysis of KONSAR study data from 2005 and 2007. Yonsei Med J 51(6):901-911
4. Kim JM, Park ES, Jeong JS, Kim KM, Kim JM, Oh HS, Yoon SW, Chang HS, Chang KH, Lee SI, Lee MS, Song JH, Kang MW, Park SC, Choe KW, Pai CH (2000) Multicenter surveillance study for nosocomial infections in major hospitals in Korea. Nosocomial Infection Surveillance Committee of the Korean Society for Nosocomial Infection Control. Am J Infect Control 28(6):454-458
5. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40(1):135-136
6. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR (1999) Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 340(7):493-501
7. Centers for Disease Control and Prevention (CDC) (2000) Staphylococcus aureus with reduced susceptibility to vancomycin -Illinois, 1999. MMWR Morb Mortal Wkly Rep 48(51-52):1165-1167
8. Wie SH, Kang JH, Huh DH, Lee DG, Kim SI, Kim YR, Choi JH, Kim JH, Yoo JH, Hur JK, Shin WS, Kang MW (2001) Antimicrobial activities of arbekacin against clinical isolates of Staphylococcus aureus and coagulase-negative Staphylococcus species. Korean J Infect Dis 33(4):254-260
9. Watanabe T, Ohashi K, Matsui K, Kubota T (1997) Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 39(4):471-476
10. Kim TH, Choo EJ, Lee MS, Kim NJ, Woo JH, Ryu J, Chang MS, Yum YK (2003) Clinical efficacy and safety with arbekacin for methicillin-resistant Staphylococcus aureus (MRSA) infections. Korean J Med 65(2):239-244
11. Manjunath G, Sarnak MJ, Levey AS (2001) Prediction equations to estimate glomerular filtration rate: An update. Curr Opin Nephrol Hypertens 10(6):785-792
12. Mackowiak PA, LeMaistre CF (1987) Drug fever: A critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med 106(5):728-733
13. Choo EJ, Choi SH, Cho YW, Chung SM, Kim BN, Kim NJ et al (2002) Clinical experience with quinupristin-dalfopristin treatment for vancomycin-resistant enterococcal infection. J Korean Soc Chemother 20(1):17-24
14. Rosenthal VD, Maki DG,Mehta A, Alvarez-Moreno C, Leblebicioglu H, Higuera F, Cuellar LE,Madani N, Mitrev Z, Dueñas L, Navoa-Ng JA, Garcell HG, Raka L, Hidalgo RF, Medeiros EA, Kanj SS, Abubakar S, Nercelles P, Pratesi RD, International Nosocomial Infection Control Consortium Members (2008) International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 36(9):627-637
15. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK (2009) Methicillin-resistant Staphylococcus aureus central lineassociated bloodstream infections in US intensive care units, 1997-2007. JAMA 301(7):727-736
16. Wang G, Hindler JF, Ward KW, Bruckner DA (2006) Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44(11):3883-3886
17. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC (2008) Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46(5):668-674
18. Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K (2006) Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 50 (11):3763-3769
19. Lee DG, Chun HS, Yim DS, Choi SM, Choi JH, Yoo JH, Shin WS, Kang MW (2003) Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model. Antimicrob Agents Chemother 47(12):3768-3773
20. Hamilton-Miller JM, Shah S (1995) Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 35(6):865-868
21. Suzuki K (2003) Efficacy and safety of arbekacin for staphylococcal infection in the NICU. Pediatr Int 45(3):301-306
22. Kobayashi Y, Uchida H, Kawakami Y (1995) Arbekacin. Int J Antimicrob Agents 5(4):227-230
23. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49(4):507-514